- Home
- ANAB vs EOI Comparison
ANAB vs EOI Comparison
Compare ANAB & EOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- EOI
- Stock Information
- Founded
- ANAB 2005
- EOI 2004
- Country
- ANAB United States
- EOI United States
- Employees
- ANAB N/A
- EOI N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- EOI Finance/Investors Services
- Sector
- ANAB Health Care
- EOI Finance
- Exchange
- ANAB Nasdaq
- EOI Nasdaq
- Market Cap
- ANAB 951.1M
- EOI 835.4M
- IPO Year
- ANAB 2017
- EOI N/A
- Fundamental
- Price
- ANAB $36.12
- EOI $20.73
- Analyst Decision
- ANAB Buy
- EOI
- Analyst Count
- ANAB 12
- EOI 0
- Target Price
- ANAB $59.30
- EOI N/A
- AVG Volume (30 Days)
- ANAB 365.9K
- EOI 83.6K
- Earning Date
- ANAB 10-31-2025
- EOI 01-01-0001
- Dividend Yield
- ANAB N/A
- EOI 7.19%
- EPS Growth
- ANAB N/A
- EOI N/A
- EPS
- ANAB N/A
- EOI N/A
- Revenue
- ANAB $123,164,000.00
- EOI N/A
- Revenue This Year
- ANAB $24.36
- EOI N/A
- Revenue Next Year
- ANAB N/A
- EOI N/A
- P/E Ratio
- ANAB N/A
- EOI N/A
- Revenue Growth
- ANAB 304.17
- EOI N/A
- 52 Week Low
- ANAB $12.21
- EOI $14.36
- 52 Week High
- ANAB $38.39
- EOI $18.88
- Technical
- Relative Strength Index (RSI)
- ANAB 72.97
- EOI 49.23
- Support Level
- ANAB $33.01
- EOI $20.30
- Resistance Level
- ANAB $35.58
- EOI $20.88
- Average True Range (ATR)
- ANAB 1.67
- EOI 0.32
- MACD
- ANAB -0.05
- EOI 0.04
- Stochastic Oscillator
- ANAB 68.61
- EOI 71.93
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation.